MCOV B — Medicover AB Balance Sheet
0.000.00%
- SEK33.14bn
- SEK47.86bn
- €2.09bn
- 83
- 19
- 67
- 58
Annual balance sheet for Medicover AB, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 86.8 | 278 | 49.1 | 64.4 | 82.8 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 138 | 193 | 214 | 246 | 279 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 289 | 552 | 335 | 381 | 447 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 438 | 647 | 841 | 876 | 976 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,111 | 1,684 | 1,832 | 1,941 | 2,138 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 228 | 325 | 354 | 501 | 566 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 663 | 1,167 | 1,357 | 1,445 | 1,673 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 448 | 518 | 475 | 497 | 465 |
| Total Liabilities & Shareholders' Equity | 1,111 | 1,684 | 1,832 | 1,941 | 2,138 |
| Total Common Shares Outstanding |